SCHEMBL12848632

SCHEMBL12848632

O=C1Nc2ccccc2C1=Cc1ccc2c(-c3cncnc3)n[nH]c2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.50
MAPK1 P28482 3/20 0.50
HTT P42858 1/20 0.50
PLK4 O00444 2/20 0.47
PLK1 P53350 2/20 0.47
PDGFRB P09619 4/20 0.47
RET P07949 1/20 0.47
FLT3 P36888 1/20 0.47
KDR P35968 1/20 0.47
PSEN1 P49768 1/20 0.47
PSEN2 P49810 1/20 0.47
APH1B Q8WW43 1/20 0.47
NCSTN Q92542 1/20 0.47
APH1A Q96BI3 1/20 0.47
PSENEN Q9NZ42 1/20 0.47
TTK P33981 1/20 0.46
GSK3B P49841 1/20 0.45
RPS6KA3 P51812 1/20 0.45
ALK Q9UM73 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3796767 1.00 MAPT (0.50) MAPTMAPK1HTTPLK4PLK1
SCHEMBL3796759 1.00 MAPT (0.50) MAPTMAPK1HTTPLK4PLK1
SCHEMBL3784202 0.90 TTK (0.60) MAPTMAPK1HTTPLK4PLK1
SCHEMBL3707160 0.90 TTK (0.60) MAPTMAPK1HTTPLK4PLK1
SCHEMBL3707158 0.90 TTK (0.60) MAPTMAPK1HTTPLK4PLK1
SCHEMBL12795294 0.88 MAPT (0.51) MAPTMAPK1HTTPLK4PLK1
SCHEMBL3787845 0.83 PDGFRB (0.43) MAPTMAPK1HTTPLK4PLK1
SCHEMBL12848216 0.83 PDGFRB (0.43) MAPTMAPK1HTTPLK4PLK1
SCHEMBL3787836 0.83 PDGFRB (0.43) MAPTMAPK1HTTPLK4PLK1
SCHEMBL12848488 0.82 APP (0.65) MAPTMAPK1PLK4PLK1PDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8765748-B2 Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer UNIVERSITY HEALTH NETWORK (CA) 2014-07-01 US disclosed
US-20110065702-A1 INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER UNIVERSITY HEALTH NETWORK 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065702-A1 INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER TNNI3K, ABL1, TK1 MAPT 964/4885MAPK1 382/4885HTT 2832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.